دورية أكاديمية
Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food.
العنوان: | Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food. |
---|---|
المؤلفون: | Charbogne P; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada., Gardon O; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch., Martín-García E; Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain., Keyworth HL; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom., Matsui A; Section on Neuronal Structure, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland., Mechling AE; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany., Bienert T; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany., Nasseef MT; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada., Robé A; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch., Moquin L; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada., Darcq E; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada., Ben Hamida S; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada., Robledo P; Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain., Matifas A; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch., Befort K; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Laboratoire de Neurosciences Cognitives et Adaptatives, Université de Strasbourg Faculté de Psychologie, Strasbourg, France; Laboratoire de Neurosciences Cognitives et Adaptatives, UMR 7364, Centre National de la Recherche Scientifique, Strasbourg, France., Gavériaux-Ruff C; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch., Harsan LA; Laboratory of Engineering, Informatics and Imaging, Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg, Strasbourg, France; University Hospital Strasbourg, Department of Biophysics and Nuclear Medicine, Strasbourg, France; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany., von Elverfeldt D; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany., Hennig J; Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Faculty of Medicine, Freiburg, Germany., Gratton A; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada., Kitchen I; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom., Bailey A; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom; Institute of Medical and Biomedical Education, St. George's University of London, London, United Kingdom., Alvarez VA; Section on Neuronal Structure, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland., Maldonado R; Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, PRBB, Barcelona, Spain., Kieffer BL; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Illkirch; Douglas Mental Health Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada. Electronic address: brigitte.kieffer@douglas.mcgill.ca. |
المصدر: | Biological psychiatry [Biol Psychiatry] 2017 May 01; Vol. 81 (9), pp. 778-788. Date of Electronic Publication: 2016 Dec 26. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 0213264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2402 (Electronic) Linking ISSN: 00063223 NLM ISO Abbreviation: Biol Psychiatry Subsets: MEDLINE |
أسماء مطبوعة: | Publication: New York, NY : Elsevier Original Publication: New York, Plenum Pub. Corp. |
مواضيع طبية MeSH: | Feeding Behavior/*physiology , GABAergic Neurons/*physiology , Heroin/*administration & dosage , Motivation/*physiology , Narcotics/*administration & dosage , Prosencephalon/*physiology , Receptors, Opioid, mu/*physiology, Animals ; Conditioning, Classical/drug effects ; Conditioning, Classical/physiology ; Corpus Striatum/drug effects ; Corpus Striatum/metabolism ; Corpus Striatum/physiology ; Female ; GABAergic Neurons/metabolism ; Inhibitory Postsynaptic Potentials/drug effects ; Male ; Mice ; Mice, Knockout ; Morphine/administration & dosage ; Motivation/drug effects ; Neural Pathways/physiology ; Prosencephalon/drug effects ; Prosencephalon/metabolism ; Receptors, Opioid, mu/genetics ; Ventral Tegmental Area/drug effects ; Ventral Tegmental Area/physiology |
مستخلص: | Background: Mu opioid receptors (MORs) are central to pain control, drug reward, and addictive behaviors, but underlying circuit mechanisms have been poorly explored by genetic approaches. Here we investigate the contribution of MORs expressed in gamma-aminobutyric acidergic forebrain neurons to major biological effects of opiates, and also challenge the canonical disinhibition model of opiate reward. Methods: We used Dlx5/6-mediated recombination to create conditional Oprm1 mice in gamma-aminobutyric acidergic forebrain neurons. We characterized the genetic deletion by histology, electrophysiology, and microdialysis; probed neuronal activation by c-Fos immunohistochemistry and resting-state functional magnetic resonance imaging; and investigated main behavioral responses to opiates, including motivation to obtain heroin and palatable food. Results: Mutant mice showed MOR transcript deletion mainly in the striatum. In the ventral tegmental area, local MOR activity was intact, and reduced activity was only observed at the level of striatonigral afferents. Heroin-induced neuronal activation was modified at both sites, and whole-brain functional networks were altered in live animals. Morphine analgesia was not altered, and neither was physical dependence to chronic morphine. In contrast, locomotor effects of heroin were abolished, and heroin-induced catalepsy was increased. Place preference to heroin was not modified, but remarkably, motivation to obtain heroin and palatable food was enhanced in operant self-administration procedures. Conclusions: Our study reveals dissociable MOR functions across mesocorticolimbic networks. Thus, beyond a well-established role in reward processing, operating at the level of local ventral tegmental area neurons, MORs also moderate motivation for appetitive stimuli within forebrain circuits that drive motivated behaviors. (Copyright © 2017 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.) |
التعليقات: | Erratum in: Biol Psychiatry. 2018 Dec 1;84(11):857. (PMID: 30409268) |
References: | Eur J Pharmacol. 1996 Jan 11;295(2-3):137-46. (PMID: 8720577) J Neurosci. 2014 Mar 19;34(12):4239-50. (PMID: 24647944) Annu Rev Psychol. 1989;40:191-225. (PMID: 2648975) Biol Psychiatry. 2015 Feb 15;77(4):404-15. (PMID: 25444168) Neuroimage. 2014 Aug 1;96:203-15. (PMID: 24718287) J Neurosci. 1995 May;15(5 Pt 1):3622-39. (PMID: 7751934) Science. 2004 Jun 25;304(5679):1983-6. (PMID: 15218152) Eur J Neurosci. 2005 Jun;21(12):3301-9. (PMID: 16026468) Physiol Rev. 2001 Jan;81(1):299-343. (PMID: 11152760) Neuropsychopharmacology. 2001 Jul;25(1):41-54. (PMID: 11377918) Ann N Y Acad Sci. 2008;1129:175-84. (PMID: 18591478) Curr Opin Pharmacol. 2009 Feb;9(1):65-73. (PMID: 19162544) Eur J Pharmacol. 2002 Jun 20;446(1-3):103-9. (PMID: 12098591) Br J Pharmacol. 2015 Jan;172(2):469-81. (PMID: 24467517) Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11318-11323. (PMID: 27647894) Physiol Rev. 2009 Oct;89(4):1379-412. (PMID: 19789384) Trends Neurosci. 2015 Apr;38(4):217-25. (PMID: 25637939) J Neurosci. 2014 Jan 15;34(3):1057-66. (PMID: 24431463) Eur J Neurosci. 2002 Oct;16(7):1377-89. (PMID: 12405997) Brain Res. 2001 Mar 16;894(2):311-5. (PMID: 11251207) Int J Neuropsychopharmacol. 2009 Apr;12(3):343-56. (PMID: 18752721) Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11603-11608. (PMID: 27671662) PLoS One. 2013 Sep 12;8(9):e74706. (PMID: 24069332) J Neurosci. 2007 Sep 5;27(36):9721-8. (PMID: 17804632) Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1263-71. (PMID: 12502012) Nat Neurosci. 2014 Mar;17(3):400-6. (PMID: 24487234) Eur J Neurosci. 2014 Jun;39(11):1796-809. (PMID: 24580812) Neuropharmacology. 2014 Jan;76 Pt B:204-17. (PMID: 24035914) Eur J Neurosci. 2010 Feb;31(4):742-53. (PMID: 20384817) J Clin Oncol. 2014 Jun 1;32(16):1655-61. (PMID: 24799496) Neuron. 2014 Jun 18;82(6):1346-56. (PMID: 24857021) Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1544-9. (PMID: 9037090) Neuropsychopharmacology. 2010 Jan;35(1):217-38. (PMID: 19710631) Eur J Pharmacol. 1995 Mar 14;275(3):251-8. (PMID: 7768292) Neuron. 2012 Mar 22;73(6):1173-83. (PMID: 22445344) Nat Neurosci. 2006 Mar;9(3):443-52. (PMID: 16491081) Neuropharmacology. 2008 Mar;54(3):475-86. (PMID: 18082850) Pharmacol Biochem Behav. 2000 May;66(1):189-97. (PMID: 10837860) Naunyn Schmiedebergs Arch Pharmacol. 2000 Jun;361(6):584-9. (PMID: 10882032) Synapse. 2001 Jun 1;40(3):184-92. (PMID: 11304756) Neuron. 2006 Aug 17;51(4):455-66. (PMID: 16908411) J Neurosci. 1992 Feb;12(2):483-8. (PMID: 1346804) Nat Neurosci. 2014 Feb;17(2):254-61. (PMID: 24413699) Brain Struct Funct. 2015 Mar;220(2):677-702. (PMID: 24623156) PLoS One. 2009;4(2):e4410. (PMID: 19198656) Neurosci Lett. 1981 Nov 18;27(1):69-73. (PMID: 6120489) Nat Rev Neurosci. 2013 Sep;14(9):609-25. (PMID: 23942470) J Neurosci. 2015 Apr 1;35(13):5247-59. (PMID: 25834050) J Comp Neurol. 2016 Jun 1;524(8):1646-52. (PMID: 26788716) Annu Rev Neurosci. 2007;30:289-316. (PMID: 17376009) Addict Biol. 2012 Jul;17(4):770-82. (PMID: 22264360) J Neurosci Methods. 2014 Feb 15;223:50-68. (PMID: 24200508) Psychopharmacology (Berl). 1984;84(2):167-73. (PMID: 6438676) Neuropharmacology. 1979 Jul;18(7):633-7. (PMID: 40155) Nature. 2016 Feb 11;530(7589):219-22. (PMID: 26840481) Brain Res. 1999 Feb 13;818(2):335-45. (PMID: 10082819) Biol Psychiatry. 2011 Apr 1;69(7):700-3. (PMID: 21168121) Life Sci. 1981 Feb 2;28(5):551-5. (PMID: 7207031) Nature. 2012 Nov 8;491(7423):212-7. (PMID: 23064228) Nature. 1996 Oct 31;383(6603):819-23. (PMID: 8893006) J Pharmacol Exp Ther. 2004 Feb;308(2):667-78. (PMID: 14610238) Neurosci Biobehav Rev. 2010 Nov;35(2):129-50. (PMID: 20149820) Neuropharmacology. 2004;47 Suppl 1:227-41. (PMID: 15464140) J Neurosci. 1994 Apr;14(4):1978-84. (PMID: 8158252) Eur J Neurosci. 2003 Jan;17(2):315-24. (PMID: 12542668) |
معلومات مُعتمدة: | P50 DA005010 United States DA NIDA NIH HHS; U01 AA016658 United States AA NIAAA NIH HHS; ZIA AA000421 United States ImNIH Intramural NIH HHS |
فهرسة مساهمة: | Keywords: Conditional gene knockout; Dopamine; Motivation; Mu opioid receptor; Opiate; Reward |
المشرفين على المادة: | 0 (Narcotics) 0 (Receptors, Opioid, mu) 70D95007SX (Heroin) 76I7G6D29C (Morphine) |
تواريخ الأحداث: | Date Created: 20170211 Date Completed: 20170815 Latest Revision: 20210109 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC5386808 |
DOI: | 10.1016/j.biopsych.2016.12.022 |
PMID: | 28185645 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1873-2402 |
---|---|
DOI: | 10.1016/j.biopsych.2016.12.022 |